Insider Transactions in Q1 2016 at Cvs Health Corp (CVS)
Insider Transaction List (Q1 2016)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 09
2016
|
Larry J Merlo Director |
SELL
Open market or private sale
|
Direct |
38,247
-14.64%
|
$3,824,700
$100.0 P/Share
|
|
Mar 09
2016
|
Larry J Merlo Director |
BUY
Exercise of conversion of derivative security
|
Direct |
38,247
+12.77%
|
$1,376,892
$36.23 P/Share
|
|
Mar 09
2016
|
Troyen A Brennan EVP and Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
6,755
-8.85%
|
$675,500
$100.0 P/Share
|
|
Mar 02
2016
|
Richard M Bracken Director |
BUY
Grant, award, or other acquisition
|
Direct |
19
+0.67%
|
$1,862
$98.63 P/Share
|
|
Feb 29
2016
|
Jonathan C Roberts EVP & Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,748
+15.39%
|
$1,624,556
$97.17 P/Share
|
|
Feb 29
2016
|
Andrew Sussman EVP, Clinical Services |
BUY
Grant, award, or other acquisition
|
Direct |
1,675
+17.11%
|
$162,475
$97.17 P/Share
|
|
Feb 29
2016
|
Andrew Sussman EVP, Clinical Services |
BUY
Grant, award, or other acquisition
|
Direct |
5,024
+26.57%
|
$487,328
$97.17 P/Share
|
|
Feb 29
2016
|
Larry J Merlo Director |
BUY
Grant, award, or other acquisition
|
Direct |
61,412
+21.59%
|
$5,956,964
$97.17 P/Share
|
|
Feb 29
2016
|
David M Denton EVP and CFO |
BUY
Grant, award, or other acquisition
|
Direct |
16,748
+11.47%
|
$1,624,556
$97.17 P/Share
|
|
Feb 29
2016
|
Troyen A Brennan EVP and Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
14,515
+15.97%
|
$1,407,955
$97.17 P/Share
|
|
Feb 29
2016
|
Thomas M Moriarty EVP & General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
13,957
+37.43%
|
$1,353,829
$97.17 P/Share
|
|
Feb 29
2016
|
Helena Foulkes EVP & President-CVS Pharmacy |
BUY
Grant, award, or other acquisition
|
Direct |
8,932
+17.85%
|
$866,404
$97.17 P/Share
|
|
Feb 29
2016
|
Lisa Bisaccia Former EVP & Chief HR Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,932
+22.98%
|
$866,404
$97.17 P/Share
|
|
Feb 29
2016
|
Stephen J Gold EVP & CIO |
BUY
Grant, award, or other acquisition
|
Direct |
7,816
+27.97%
|
$758,152
$97.17 P/Share
|
|
Feb 29
2016
|
Eva C Boratto EVP & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
1,415
+6.23%
|
$137,255
$97.17 P/Share
|
|
Feb 29
2016
|
Eva C Boratto EVP & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
2,233
+7.2%
|
$216,601
$97.17 P/Share
|
|
Feb 29
2016
|
J. David Joyner President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
5,582
+8.17%
|
$541,454
$97.17 P/Share
|
|
Feb 27
2016
|
Eva C Boratto EVP & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
192
-0.72%
|
$18,624
$97.66 P/Share
|
|
Feb 27
2016
|
Robert O. Kraft EVP and President - Omnicare |
SELL
Payment of exercise price or tax liability
|
Direct |
422
-6.17%
|
$40,934
$97.66 P/Share
|
|
Feb 19
2016
|
Eva C Boratto EVP & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
463
-1.74%
|
$44,911
$97.59 P/Share
|
|
Feb 18
2016
|
Eva C Boratto EVP & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
346
-1.35%
|
$33,216
$96.89 P/Share
|
|
Feb 11
2016
|
Jonathan C Roberts EVP & Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
23,355
-44.92%
|
$2,148,660
$92.86 P/Share
|
|
Feb 01
2016
|
Larry J Merlo Director |
SELL
Open market or private sale
|
Direct |
46,393
-22.3%
|
$4,453,728
$96.14 P/Share
|
|
Feb 01
2016
|
Larry J Merlo Director |
BUY
Exercise of conversion of derivative security
|
Direct |
46,393
+18.24%
|
$1,299,004
$28.1 P/Share
|
|
Jan 11
2016
|
Larry J Merlo Director |
SELL
Open market or private sale
|
Direct |
46,393
-22.3%
|
$4,407,335
$95.0 P/Share
|
|
Jan 11
2016
|
Larry J Merlo Director |
BUY
Exercise of conversion of derivative security
|
Direct |
46,393
+18.24%
|
$1,299,004
$28.1 P/Share
|
|
Jan 04
2016
|
Anne A. Finucane Director |
SELL
Open market or private sale
|
Indirect |
2,000
-11.96%
|
$190,000
$95.87 P/Share
|
|
Jan 02
2016
|
Helena Foulkes EVP & President-CVS Pharmacy |
SELL
Payment of exercise price or tax liability
|
Direct |
748
-2.28%
|
$71,808
$96.46 P/Share
|